Geoff Meacham
Stock Analyst at Citigroup
(4.40)
# 344
Out of 5,115 analysts
281
Total ratings
59.32%
Success rate
15.02%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $110 | $83.33 | +32.01% | 7 | Dec 9, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $98 → $115 | $88.84 | +29.45% | 4 | Dec 8, 2025 | |
| JANX Janux Therapeutics | Maintains: Buy | $58 → $49 | $14.31 | +242.42% | 3 | Dec 2, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $26 | $25.03 | +3.88% | 7 | Dec 2, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $9 → $8 | $2.17 | +268.66% | 6 | Nov 18, 2025 | |
| PTCT PTC Therapeutics | Maintains: Neutral | $50 → $75 | $78.37 | -4.30% | 10 | Nov 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $240 → $235 | $229.89 | +2.22% | 21 | Nov 3, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $660 → $700 | $783.71 | -10.68% | 24 | Oct 29, 2025 | |
| RNA Avidity Biosciences | Downgrades: Neutral | $75 → $72 | $72.20 | -0.27% | 8 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Neutral | $30 → $28 | $32.75 | -14.50% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $35.65 | +40.25% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $42.49 | +17.67% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $12.49 | +60.13% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $56.71 | +63.99% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $84 → $95 | $106.45 | -10.76% | 8 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $135 | $125.67 | +7.42% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $575 | $462.99 | +24.19% | 6 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $6.11 | +129.13% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $305 → $310 | $333.96 | -7.17% | 13 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $125 → $135 | $176.33 | -23.44% | 15 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $39.25 | +7.01% | 3 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $76.53 | -29.44% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $66.00 | +66.67% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $6.94 | -13.54% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $140 | $95.03 | +47.32% | 2 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $1.81 | -44.75% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $78.03 | +21.75% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $103 | $60.16 | +71.21% | 3 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $1.71 | +133.92% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $1,076.98 | +2.14% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $38.55 | -48.12% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $26.01 | +19.18% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $207.78 | -18.18% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $68 → $60 | $54.71 | +9.67% | 8 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $4.31 | +85.61% | 4 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.48 | +1,048.65% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $2.25 | +966.67% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $15.36 | -73.96% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $3.43 | +716.33% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $1.04 | +3,169.23% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $3.96 | +783.84% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $29.49 | +1,680.26% | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.22 | +3,342.62% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $8.26 | +142.13% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.45 | +4,394.38% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $5.96 | +51.01% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $14.45 | +315.22% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $26.86 | -14.37% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $100.44 | -18.36% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $514.64 | -81.54% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $18.97 | +321.72% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $146.93 | -8.12% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.69 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $3.26 | +513.50% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $10.81 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $400.69 | -60.57% | 5 | Nov 8, 2017 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $83.33
Upside: +32.01%
Protagonist Therapeutics
Dec 8, 2025
Maintains: Buy
Price Target: $98 → $115
Current: $88.84
Upside: +29.45%
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $14.31
Upside: +242.42%
Pfizer
Dec 2, 2025
Reinstates: Neutral
Price Target: $26
Current: $25.03
Upside: +3.88%
Acumen Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.17
Upside: +268.66%
PTC Therapeutics
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $78.37
Upside: -4.30%
AbbVie
Nov 3, 2025
Maintains: Neutral
Price Target: $240 → $235
Current: $229.89
Upside: +2.22%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $783.71
Upside: -10.68%
Avidity Biosciences
Oct 27, 2025
Downgrades: Neutral
Price Target: $75 → $72
Current: $72.20
Upside: -0.27%
Moderna
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $32.75
Upside: -14.50%
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $35.65
Upside: +40.25%
Oct 17, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $42.49
Upside: +17.67%
Oct 17, 2025
Maintains: Buy
Price Target: $12 → $20
Current: $12.49
Upside: +60.13%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $56.71
Upside: +63.99%
Oct 13, 2025
Reinstates: Neutral
Price Target: $84 → $95
Current: $106.45
Upside: -10.76%
Oct 8, 2025
Maintains: Buy
Price Target: $125 → $135
Current: $125.67
Upside: +7.42%
Oct 2, 2025
Maintains: Buy
Price Target: $550 → $575
Current: $462.99
Upside: +24.19%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $6.11
Upside: +129.13%
Aug 6, 2025
Maintains: Neutral
Price Target: $305 → $310
Current: $333.96
Upside: -7.17%
Aug 1, 2025
Maintains: Neutral
Price Target: $125 → $135
Current: $176.33
Upside: -23.44%
Jul 22, 2025
Maintains: Buy
Price Target: $40 → $42
Current: $39.25
Upside: +7.01%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $76.53
Upside: -29.44%
Jun 17, 2025
Initiates: Buy
Price Target: $110
Current: $66.00
Upside: +66.67%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $6.94
Upside: -13.54%
May 6, 2025
Maintains: Buy
Price Target: $145 → $140
Current: $95.03
Upside: +47.32%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $1.81
Upside: -44.75%
Mar 13, 2025
Initiates: Buy
Price Target: $95
Current: $78.03
Upside: +21.75%
Feb 20, 2025
Maintains: Buy
Price Target: $99 → $103
Current: $60.16
Upside: +71.21%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $1.71
Upside: +133.92%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $1,076.98
Upside: +2.14%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $38.55
Upside: -48.12%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $26.01
Upside: +19.18%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $207.78
Upside: -18.18%
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $54.71
Upside: +9.67%
Aug 21, 2023
Maintains: Underperform
Price Target: $10 → $8
Current: $4.31
Upside: +85.61%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.48
Upside: +1,048.65%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $2.25
Upside: +966.67%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $15.36
Upside: -73.96%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $3.43
Upside: +716.33%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $1.04
Upside: +3,169.23%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $3.96
Upside: +783.84%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $29.49
Upside: +1,680.26%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.22
Upside: +3,342.62%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $8.26
Upside: +142.13%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.45
Upside: +4,394.38%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $5.96
Upside: +51.01%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $14.45
Upside: +315.22%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $26.86
Upside: -14.37%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $100.44
Upside: -18.36%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $514.64
Upside: -81.54%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $18.97
Upside: +321.72%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $146.93
Upside: -8.12%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $9.69
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $3.26
Upside: +513.50%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $10.81
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $400.69
Upside: -60.57%